MANAGEMENT OF ASCITES IN CIRRHOSIS
https://doi.org/10.51523/2708-6011.2012-9-3-6
Abstract
Ascites is a common complication of liver cirrhosis associated with a poor prognosis. The treatment of ascites requires dietary sodium restriction and the judicious use of diuretics. Management of refractory ascites in cirrhosis requires treatments of repeat largevolumeparacentesis (LVP) or the insertion of a transjugular intrahepatic portosystemic shunt (TIPS), and assessment for liver transplantation. Potential new treatment options for ascites include the use of various vasoconstrictors, vasopressin V2 receptor antagonists, or the insertion of a peritoneo-vesical shunt.
References
1. Wong, F. Management of ascites in cirrhosis / F. Wong // J. Gastroenterol. Hepatol. - 2012. -Vol. 27. -P. 11-20.
2. D’Amico, G. Natural history andprognostic indicators of survival in cirrhosis: a systematic review of118 studies / G. D’Amico, G. Garcia-Tsao, L. Pagliaro // J. Hepatol. - 2006. - Vol. 44. - Р. 217-231.
3. Natural history of patients hospitalized for management of cirrhotic ascites / R. Planas [et al.] // Clin. Gastroenterol. Hepatol. - 2006. - Vol. 4. - Р. 1385-1394.
4. Guevara, M. Hepatorenal syndrome / M. Guevara, V. Arroyo // Expert Opin. Pharmacother. - 2011. - Vol. 12. - Р. 1405-1417.
5. Cárdenas, A. Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites / A. Cárdenas, V. Arroyo // Best Pract Res Clin. Endocrinol. Metab. - 2003. - Vol. 17. - Р. 607-622.
6. The management of ascites - report on the consensus conference of the International Ascites Club / K. P. Moore [et al.] // Hepatology. - 2003. - Vol. 38. - Р. 258-266.
7. Refractory ascites, pathogenesis, definition, and therapy of a severe complication in cirrhotic patients / F. Salerno [et al.] // Liver Int. - 2010. - Vol. 30. - Р. 937-947.
8. Runyon, B. A. AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update / B. A. Runyon // Hepatology. - 2009. - Vol. 49. - Р. 2087-2107.
9. Leung, W. Medical management of ascites/ W. Leung, F. Wong // Expert Opin. Pharmacother. - 2011. - Vol. 12. - P. 1269-1283.
10. Wong, F. Drug insight: the role of albumin in the management ofchronic liver disease / F. Wong // Nat. Clin. Pract. Gastroenterol. Hepatol. - 2007. - Vol. 4. - Р. 43-51.
11. Long-term albumininfusion improves survival in patients with cirrhosis and ascites: anunblinded randomized trial / R. G. Romanelli [et al.] // World J. Gastroenterol. - 2006. - Vol. 12. - Р. 1403-1407.
12. The effects of VPA-985, a vasopressin receptor antagonist, on water metabolism in patients with hyponatremia: a multi-center randomized placebo controlled trial / F. Wong [et al.] // Hepatology. - 2003. - Vol. 37. - Р. 182-191.
13. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia / R. W. Schrier [et al.] // N. Engl. J. Med. - 2006. - Vol. 355. - Р. 2099-2112.
14. Ginès, P. Effects of Satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium concentration in patients with cirrhosis and hyponatremia / P. Ginès [et al.] // Hepatology. - 2008. - Vol. 48. - Р. 204-213.
15. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity / F. Wong, [et al.] // Gut. - 2011 (in press).
16. Effects of M0002, a novel V2 antagonist on sodium levels and weight gain affected by water accumulation in cirrhotic patients with ascites / F. Nevens [et al.] // J. Hepatol. - 2009. - Vol. 50. - Р. 76.
17. Colombato, L. The role of transjugular intrahepatic porto-systemicshunt (TIPS) in the management of portal hypertension / L. Colombato // J. Clin. Gastroenterol. - 2007. - Vol. 41. - Р. 344-351.
18. Transjugularintrahepatic portosystemic shunt for refractory ascites, ameta-analysis of individual patient data / F. Salerno [et al.] // Gastroenterology. - 2007. - Vol. 133. - Р. 825-834.
Review
For citations:
Malaeva E.G. MANAGEMENT OF ASCITES IN CIRRHOSIS. Health and Ecology Issues. 2012;(3):28-35. (In Russ.) https://doi.org/10.51523/2708-6011.2012-9-3-6
Views: 248
Email this article 